Last reviewed · How we verify
Lipopolysaccharide endotoxin
At a glance
| Generic name | Lipopolysaccharide endotoxin |
|---|---|
| Also known as | (CCRE)LPS endotoxin from E. Coli 0:113 maintained by NIH |
| Sponsor | John Sundy |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Fever
- Anxiety
- Vasovagal Reaction
- UTI
Key clinical trials
- Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use (PHASE2)
- Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease (NA)
- Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns
- Hemoperfusion Efferon LPS During Cardiac Surgery Using Cardiopulmonary Bypass (NA)
- Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis (NA)
- Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
- Effect of Endotoxin on Alcohol Consumption (PHASE2)
- Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipopolysaccharide endotoxin CI brief — competitive landscape report
- Lipopolysaccharide endotoxin updates RSS · CI watch RSS
- John Sundy portfolio CI